They just announced after market close that John Crowley will be presenting. This is a late entry into the conference, and I believe it is to present the POMP data, or to tell the world that their Fabry drug's secondary endpoints were reached even though the placebo group results falsely ruined the latest trial. The stock is already up to 2.96 after hours, and with a big short population, this could pop before the weekend.
It probably won't be the Fabry secondary endpoint, that isn't due until February.
The 6-month secondary endpoints in Study 011 continue to be analyzed and will be presented at the Lysosomal Disease Network WORLD Symposium (LDN WORLD), to be held February 12-15, 2013, in Orlando, Florida. Secondary endpoints include urine GL-3 and renal function (iohexol GFR, eGFR and 24-hour urine protein).